Home Newsfeeds Jefferies Upgrades Wynn Resorts to Buy

Jefferies Upgrades Wynn Resorts to Buy

Jefferies analyst David Katz upgrades Wynn Resorts (NASDAQ:WYNN) from Hold to Buy.

byBenzinga Newsdesk

September 26, 2022

1 minute read

Jefferies analyst David Katz upgrades Wynn Resorts (NASDAQ:WYNN) from Hold to Buy.

Mizuho Maintains Buy on NIO, Lowers Price Target to $42

By Benzinga Newsdesk

September 8, 6:55 AM

Mizuho analyst Vijay Rakesh maintains NIO (NYSE:NIO) with a Buy and lowers the price target from $48 to $42.

NIO

Casa CEO Warns Of Binance’s ‘Abnormal’ Activities, Urges Users To Withdraw Funds

By Murtuza Merchant

October 26, 2:23 PM

Bitcoin (CRYPTO: BTC) self-custody firm CASA CEO Nick Neuman on Thursday voiced concerns regarding what he said are unusual activities surrounding global cryptocurrency exchange Binance and its U.S. affiliate Binance.US.

$CEL

Nordson’s Steps To Diversify Despite Volatility, Margin Boost Initiatives Win Analyst Attention Who Prefers Buying The Dips

By Anusuya Lahiri

February 22, 1:16 PM

KeyBanc analyst Jeffrey Hammond upgraded Nordson Corp (NASDAQ:NDSN) from Sector Weight to Overweight and a $255 price target. Nordson reported Q1 sales…

NDSN

Nkarta Announces Departure Of Nadir Mahmood Resigning As Chief Financial & Business Officer, Will Remain Until June 30, 2023; Clinical Updates On Track For NKX101 In First Half Of 2023 And NKX019 In Full Year 2023

By Happy Mohamed

March 30, 4:21 PM

Clinical updates on track for NKX101 in first half of 2023 and NKX019 in full year 2023 SOUTH SAN FRANCISCO, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage

NKTX

Jefferies Upgrades Wynn Resorts to Buy

Related Posts

Mizuho Maintains Buy on NIO, Lowers Price Target to $42

Casa CEO Warns Of Binance’s ‘Abnormal’ Activities, Urges Users To Withdraw Funds

Nordson’s Steps To Diversify Despite Volatility, Margin Boost Initiatives Win Analyst Attention Who Prefers Buying The Dips

Nkarta Announces Departure Of Nadir Mahmood Resigning As Chief Financial & Business Officer, Will Remain Until June 30, 2023; Clinical Updates On Track For NKX101 In First Half Of 2023 And NKX019 In Full Year 2023